Bezpečnost léčby dabigatran etexilátem
| Title in English | Safety of therapy with dabigatran etexilate |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Proceedings |
| Conference | XVIII. Brněnský geriatrický den |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | dabigatran; bleeding; idarucizumab; antidote |
| Description | Bleeding still represents the most feared complication of anticoagulant therapy, despite its lower incidence in patients on new antithrombotics. The management of bleeding mostly consists of nonspecific therapeutic measures, in case of dabigatran there is a specific antidote available (idarucizumab). |